Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $117.00 Average Price Target from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has earned a consensus rating of “Moderate Buy” from the fourteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $117.00.

MIRM has been the topic of several analyst reports. Raymond James Financial reiterated a “strong-buy” rating and issued a $110.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. HC Wainwright lifted their price objective on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Leerink Partners dropped their price objective on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd.

Insider Activity

In other Mirum Pharmaceuticals news, Director Patrick J. Heron acquired 131,425 shares of the stock in a transaction on Friday, January 23rd. The shares were bought at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the acquisition, the director owned 459,010 shares of the company’s stock, valued at $31,433,004.80. This trade represents a 40.12% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Eric Bjerkholt sold 1,421 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total value of $132,621.93. Following the transaction, the chief financial officer owned 42,127 shares in the company, valued at $3,931,712.91. The trade was a 3.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,136 shares of company stock valued at $4,352,029 over the last ninety days. 14.36% of the stock is currently owned by company insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Cullen Frost Bankers Inc. acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at $32,000. CIBC Private Wealth Group LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth $32,000. MCF Advisors LLC boosted its position in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth $33,000.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $89.78 on Tuesday. Mirum Pharmaceuticals has a fifty-two week low of $36.88 and a fifty-two week high of $109.28. The company has a market capitalization of $5.42 billion, a price-to-earnings ratio of -187.04 and a beta of 0.52. The firm has a 50-day simple moving average of $95.13 and a 200-day simple moving average of $80.50. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). The company had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The business’s revenue was up 49.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.00 EPS. On average, equities research analysts anticipate that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.